Comparative activity of carbapenem testing (the COMPACT study) in Turkey

Basit Öğe Kaydı
dc.contributor.authorLeblebicioglu, Hakan
dc.contributor.authorCakir, Nedim
dc.contributor.authorCelen, Mustafa
dc.contributor.authorKurt, Halil
dc.contributor.authorBaris, Hakan
dc.contributor.authorLaeuffer, Joerg
dc.date.accessioned2024-04-24T17:14:51Z
dc.date.available2024-04-24T17:14:51Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT) study centres in Turkey. Methods: Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species confirmation as well as limited susceptibility and quality-control testing. Results: Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and imipenem, respectively, were 32, >= 64, and >= 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against Enterobacteriaceae; and >= 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher. Conclusions: Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.en_US
dc.description.sponsorshipJanssen EMEAen_US
dc.description.sponsorshipThis work was supported by Janssen EMEA. The decision to submit this article for publication was made by Janssen and the authors. No financial support or honorarium was given to the non-Janssen authors for the development of this manuscript. H. Baris and J. Laeuffer are employees of Janssen EMEA. These authors were not awarded any additional support outside of their salaries for their participation in this study. Editorial assistance was provided by Phase Five Communications Inc., which was funded by Janssen EMEA.en_US
dc.identifier.doi10.1186/1471-2334-12-42
dc.identifier.issn1471-2334
dc.identifier.pmid22340940
dc.identifier.scopus2-s2.0-84856929992
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1186/1471-2334-12-42
dc.identifier.urihttps://hdl.handle.net/11468/18227
dc.identifier.volume12en_US
dc.identifier.wosWOS:000301448400001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofBmc Infectious Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keyword]en_US
dc.titleComparative activity of carbapenem testing (the COMPACT study) in Turkeyen_US
dc.titleComparative activity of carbapenem testing (the COMPACT study) in Turkey
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu